Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Analysis of 122 triplet and one quadruplet pregnancies after single embryo transfer in Japan.

Yamashita S, Ikemoto Y, Ochiai A, Yamada S, Kato K, Ohno M, Segawa T, Nakaoka Y, Toya M, Kawachiya S, Sato Y, Takahashi T, Takeuchi S, Nomiyama M, Tabata C, Fujiwara T, Okamoto S, Kawamura T, Kawagoe J, Yamada M, Sato Y, Marumo G, Sugiyama R, Kuroda K.

Reprod Biomed Online. 2020 Mar;40(3):374-380. doi: 10.1016/j.rbmo.2019.11.008. Epub 2019 Nov 29.

PMID:
32033910
2.

Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis-associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects.

Kawakubo M, Tanaka M, Ochi K, Watanabe A, Saka-Tanaka M, Kanamori Y, Yoshioka N, Yamashita S, Goto M, Itoh M, Shirakawa I, Kanai S, Suzuki H, Sawada M, Ito A, Ishigami M, Fujishiro M, Arima H, Ogawa Y, Suganami T.

Sci Rep. 2020 Jan 22;10(1):983. doi: 10.1038/s41598-020-57935-6.

3.

Side-chain oxysterols suppress the transcription of CTP: Phosphoethanolamine cytidylyltransferase and 3-hydroxy-3-methylglutaryl-CoA reductase by inhibiting the interaction of p300 and NF-Y, and H3K27 acetylation.

Ando H, Horibata Y, Aoyama C, Shimizu H, Shinohara Y, Yamashita S, Sugimoto H.

J Steroid Biochem Mol Biol. 2019 Dec;195:105482. doi: 10.1016/j.jsbmb.2019.105482. Epub 2019 Sep 30.

PMID:
31580889
4.

TGR5 Activation Modulates an Inhibitory Effect on Liver Fibrosis Development Mediated by Anagliptin in Diabetic Rats.

Kaya D, Kaji K, Tsuji Y, Yamashita S, Kitagawa K, Ozutsumi T, Fujinaga Y, Takaya H, Kawaratani H, Moriya K, Namisaki T, Akahane T, Yoshiji H.

Cells. 2019 Sep 26;8(10). pii: E1153. doi: 10.3390/cells8101153.

5.

Erratum to 'Contribution of intestinal dipeptidyl peptidase-4 inhibition for incretin-dependent improved glucose tolerance in mice' [Eur. J. Pharmacol. 859 (2019) 172521].

Yamashita S, Kawakami Y, Sato H, Sugitani S, Goto M, Kato N.

Eur J Pharmacol. 2019 Nov 5;862:172633. doi: 10.1016/j.ejphar.2019.172633. Epub 2019 Sep 10. No abstract available.

PMID:
31519353
6.

Contribution of intestinal dipeptidyl peptidase-4 inhibition for incretin-dependent improved glucose tolerance in mice.

Yamashita S, Kawakami Y, Sato H, Sugitani S, Goto M, Kato N.

Eur J Pharmacol. 2019 Sep 15;859:172521. doi: 10.1016/j.ejphar.2019.172521. Epub 2019 Jul 2. Erratum in: Eur J Pharmacol. 2019 Nov 5;862:172633.

PMID:
31276666
7.

The effectiveness of electroconvulsive therapy for psychiatric symptoms and cognitive fluctuations similar to dementia with Lewy bodies: a case report.

Izuhara M, Hashioka S, Sato T, Nishikoori H, Koike M, Matsuda H, Kanayama M, Miura S, Yamashita S, Nagahama M, Otsuki K, Hayashida M, Wake R, Miyaoka T, Inagaki M, Horiguchi J.

Psychogeriatrics. 2020 Mar;20(2):229-231. doi: 10.1111/psyg.12465. Epub 2019 Jun 4. No abstract available.

PMID:
31161654
8.

Postprandial Plasma Glucagon Kinetics in Type 2 Diabetes Mellitus: Comparison of Immunoassay and Mass Spectrometry.

Katahira T, Kanazawa A, Shinohara M, Koshibu M, Kaga H, Mita T, Tosaka Y, Komiya K, Miyatsuka T, Ikeda F, Azuma K, Takayanagi N, Ogihara T, Ohmura C, Miyachi A, Mieno E, Yamashita S, Watada H.

J Endocr Soc. 2018 Oct 26;3(1):42-51. doi: 10.1210/js.2018-00142. eCollection 2019 Jan 1.

9.

Clostridium butyricum MIYAIRI 588 as Adjunctive Therapy for Treatment-Resistant Major Depressive Disorder: A Prospective Open-Label Trial.

Miyaoka T, Kanayama M, Wake R, Hashioka S, Hayashida M, Nagahama M, Okazaki S, Yamashita S, Miura S, Miki H, Matsuda H, Koike M, Izuhara M, Araki T, Tsuchie K, Azis IA, Arauchi R, Abdullah RA, Oh-Nishi A, Horiguchi J.

Clin Neuropharmacol. 2018 Sep/Oct;41(5):151-155. doi: 10.1097/WNF.0000000000000299.

PMID:
30234616
10.

Dipeptidyl peptidase 4 inhibitor anagliptin ameliorates hypercholesterolemia in hypercholesterolemic mice through inhibition of intestinal cholesterol transport.

Goto M, Furuta S, Yamashita S, Hashimoto H, Yano W, Inoue N, Kato N, Kaku K.

J Diabetes Investig. 2018 Nov;9(6):1261-1269. doi: 10.1111/jdi.12860. Epub 2018 Jun 5.

11.

Anagliptin, a dipeptidyl peptidase-4 inhibitor, decreases macrophage infiltration and suppresses atherosclerosis in aortic and coronary arteries in cholesterol-fed rabbits.

Hirano T, Yamashita S, Takahashi M, Hashimoto H, Mori Y, Goto M.

Metabolism. 2016 Jun;65(6):893-903. doi: 10.1016/j.metabol.2016.03.010. Epub 2016 Mar 18.

PMID:
27173468
12.

Treatment of Paroxysmal Perceptual Alteration in Catatonic Schizophrenia by Switching to Aripiprazole from Risperidone: A Case Report.

Yamashita S, Miyaoka T, Nagahama M, Ieda M, Tsuchie K, Wake R, Horiguchi J.

Clin Schizophr Relat Psychoses. 2016 spring;10(1):37-40. doi: 10.3371/CSRP.YAMI.022213. Epub 2013 Sep 18.

PMID:
24047761
13.

Marked improvement in delirium with ramelteon: five case reports.

Furuya M, Miyaoka T, Yasuda H, Yamashita S, Tanaka I, Otsuka S, Wake R, Horiguchi J.

Psychogeriatrics. 2012 Dec;12(4):259-62. doi: 10.1111/j.1479-8301.2012.00422.x.

14.

Synthesis and pharmacological characterization of potent, selective, and orally bioavailable isoindoline class dipeptidyl peptidase IV inhibitors.

Kato N, Oka M, Murase T, Yoshida M, Sakairi M, Yakufu M, Yamashita S, Yasuda Y, Yoshikawa A, Hayashi Y, Shirai M, Mizuno Y, Takeuchi M, Makino M, Takeda M, Kakigami T.

Org Med Chem Lett. 2011 Sep 12;1(1):7. doi: 10.1186/2191-2858-1-7.

15.

Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor.

Kato N, Oka M, Murase T, Yoshida M, Sakairi M, Yamashita S, Yasuda Y, Yoshikawa A, Hayashi Y, Makino M, Takeda M, Mirensha Y, Kakigami T.

Bioorg Med Chem. 2011 Dec 1;19(23):7221-7. doi: 10.1016/j.bmc.2011.09.043. Epub 2011 Oct 2. Erratum in: Bioorg Med Chem. 2013 Feb 1;21(3):832-3.

PMID:
22019046
16.

The heterotrimeric G protein subunits Gα(q) and Gβ(1) have lysophospholipase D activity.

Aoyama C, Sugimoto H, Ando H, Yamashita S, Horibata Y, Sugimoto S, Satou M.

Biochem J. 2011 Dec 1;440(2):241-50. doi: 10.1042/BJ20110545.

17.

Low-density lipoprotein and oxysterols suppress the transcription of CTP: Phosphoethanolamine cytidylyltransferase in vitro.

Ando H, Horibata Y, Yamashita S, Oyama T, Sugimoto H.

Biochim Biophys Acta. 2010 Apr;1801(4):487-95. doi: 10.1016/j.bbalip.2009.12.014. Epub 2010 Jan 4.

PMID:
20045741
18.

Targeting calcium/calmodulin-dependence kinase I and II as a potential anti-proliferation remedy for endometrial carcinomas.

Takai N, Ueda T, Nasu K, Yamashita S, Toyofuku M, Narahara H.

Cancer Lett. 2009 May 18;277(2):235-43. doi: 10.1016/j.canlet.2008.12.018. Epub 2009 Jan 24.

PMID:
19168280
19.

Identification of nuclear localization and nuclear export signals in Ets2, and the transcriptional regulation of Ets2 and CTP:phosphocholine cytidylyltransferase alpha in tetradecanoyl-13-acetate or macrophage-colony stimulating factor stimulated RAW264 cells.

Okamura K, Yamashita S, Ando H, Horibata Y, Aoyama C, Takagishi K, Izumi T, Vance DE, Sugimoto H.

Biochim Biophys Acta. 2009 Mar;1791(3):173-82. doi: 10.1016/j.bbalip.2008.12.016. Epub 2009 Jan 10.

PMID:
19168148
20.

Determination of Biotinylated Proteins as an Index for Purification of Plasma Membrane using Surface Plasmon Resonance-based Optical Biosensor.

Okumura S, Akao T, Yamashita S, Ichimatsu T, Inouye K.

Cytotechnology. 2005 Jan;47(1-3):59-67. doi: 10.1007/s10616-005-3757-4.

Supplemental Content

Loading ...
Support Center